Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;25(4):223-231.
doi: 10.2174/0118715206329892240927081033.

Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger

Xueshuai Ye  1 , Yongqiang Wu  2 , Haiqiang Zhang  3
Affiliations
Review

Emerging Claudin18.2-targeting Therapy for Systemic Treatment of Gastric Cancer: Seeking Nobility Amidst Danger

Xueshuai Ye et al. Anticancer Agents Med Chem. 2025.

Abstract

Gastric cancer in advanced stages lacked effective treatment options. claudin18.2 (CLDN18.2) is a membrane protein that is crucial for close junctions in the differentiated epithelial cells of the gastric mucosa, playing a vital role in barrier function, and can be hardly recognized by immune cells due to its polarity pattern. As the polarity of gastric tumor cells changes, claudin18.2 is exposed on the cell surface, resulting in immune system recognition, and making it an ideal target. In this review, we summarized the expression regulation mechanism of claudin18.2 both in normal cells and malignant tumor cells. Besides, we analyzed the available clinical results and potential areas for future research on claudin18.2-positive gastric cancer and claudin18.2-targeting therapy. In conclusion, claudin18.2 is an ideal target for gastric cancer treatment, and the claudin18.2-targeting therapy has changed the treatment pattern of gastric cancer.

Keywords: ADC; CAR T; Claudin18.2; gastric cancer; gastric mucosa.; monoclonal antibody.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249 - DOI - PubMed
    1. Smyth E.C.; Nilsson M.; Grabsch H.I.; van Grieken N.C.T.; Lordick F.; Gastric cancer. Lancet 2020,396(10251),635-648 - DOI - PubMed
    1. Chia N.Y.; Tan P.; Molecular classification of gastric cancer. Ann Oncol 2016,27(5),763-769 - DOI - PubMed
    1. Shitara K.; Van Cutsem E.; Bang Y.J.; Fuchs C.; Wyrwicz L.; Lee K.W.; Kudaba I.; Garrido M.; Chung H.C.; Lee J.; Castro H.R.; Mansoor W.; Braghiroli M.I.; Karaseva N.; Caglevic C.; Villanueva L.; Goekkurt E.; Satake H.; Enzinger P.; Alsina M.; Benson A.; Chao J.; Ko A.H.; Wainberg Z.A.; Kher U.; Shah S.; Kang S.P.; Tabernero J.; Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer. JAMA Oncol 2020,6(10),1571-1580 - DOI - PubMed
    1. Kang Y.K.; Chen L.T.; Ryu M.H.; Oh D.Y.; Oh S.C.; Chung H.C.; Lee K.W.; Omori T.; Shitara K.; Sakuramoto S.; Chung I.J.; Yamaguchi K.; Kato K.; Sym S.J.; Kadowaki S.; Tsuji K.; Chen J.S.; Bai L.Y.; Oh S.Y.; Choda Y.; Yasui H.; Takeuchi K.; Hirashima Y.; Hagihara S.; Boku N.; Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022,23(2),234-247 - DOI - PubMed

MeSH terms